메뉴 건너뛰기




Volumn 46, Issue 1, 2009, Pages 1-11

The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: What is the clinical relevance?

Author keywords

Adipocytokines; Atherosclerosis; Dyslipidemia; Insulin resistance; Metabolic syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ADIPONECTIN; ATORVASTATIN; C REACTIVE PROTEIN; CYTOKINE; FIBRIC ACID DERIVATIVE; FIBRINOGEN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEPTIN; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; RIMONABANT; ROSIGLITAZONE; ROSUVASTATIN; SERUM AMYLOID A; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

EID: 59349121851     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-008-0057-4     Document Type: Review
Times cited : (26)

References (111)
  • 2
    • 21644456797 scopus 로고    scopus 로고
    • International Diabetes Federation IDF Executive Office, Brussels, Belgium
    • International Diabetes Federation (2006) The IDF consensus worldwide definition of the metabolic syndrome. IDF Executive Office, Brussels, Belgium. www.idf.org. Available at http://www.idf.org/webdata/docs/MetS-def-update2006. pdf. Accessed 7 Feb 2008
    • (2006) The IDF Consensus Worldwide Definition of the Metabolic Syndrome
  • 3
    • 1842590296 scopus 로고    scopus 로고
    • Insulin resistance, cardiovascular disease, and the metabolic syndrome: How well do the emperor's clothes fit?
    • GM Reaven 2004 Insulin resistance, cardiovascular disease, and the metabolic syndrome: how well do the emperor's clothes fit? Diabetes Care 27 1011 1012
    • (2004) Diabetes Care , vol.27 , pp. 1011-1012
    • Reaven, G.M.1
  • 4
    • 5644247548 scopus 로고    scopus 로고
    • Insulin resistance, haemostatic and inflammatory markers and coronary heart disease risk factors in type 2 diabetic men with and without coronary heart disease
    • 9
    • SG Wannamethee GD Lowe AG Shaper A Rumley L Lennon PH Whiner 2004 Insulin resistance, haemostatic and inflammatory markers and coronary heart disease risk factors in type 2 diabetic men with and without coronary heart disease Diabetologia 47 9 1557 1565
    • (2004) Diabetologia , vol.47 , pp. 1557-1565
    • Wannamethee, S.G.1    Lowe, G.D.2    Shaper, A.G.3    Rumley, A.4    Lennon, L.5    Whiner, P.H.6
  • 5
    • 13844298724 scopus 로고    scopus 로고
    • Endothelial inflammation in insulin resistance
    • 9459
    • A Sjoholm T Nystrom 2005 Endothelial inflammation in insulin resistance Lancet 365 9459 610 612
    • (2005) Lancet , vol.365 , pp. 610-612
    • Sjoholm, A.1    Nystrom, T.2
  • 6
    • 2442421194 scopus 로고    scopus 로고
    • Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? the common soil hypothesis revisited
    • A Ceriello E Motz 2004 Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited Arterioscler Thromb Vasc Biol 24 816 823
    • (2004) Arterioscler Thromb Vasc Biol , vol.24 , pp. 816-823
    • Ceriello, A.1    Motz, E.2
  • 8
    • 0042234050 scopus 로고    scopus 로고
    • The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X
    • 5
    • PH Black 2003 The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X Brain Behav Immun 17 5 350 364
    • (2003) Brain Behav Immun , vol.17 , pp. 350-364
    • Black, P.H.1
  • 9
    • 0037631831 scopus 로고    scopus 로고
    • Insulin resistance and chronic cardiovascular inflammatory syndrome
    • 3
    • JM Fernandez-Real W Ricart 2003 Insulin resistance and chronic cardiovascular inflammatory syndrome Endocr Rev 24 3 278 301
    • (2003) Endocr Rev , vol.24 , pp. 278-301
    • Fernandez-Real, J.M.1    Ricart, W.2
  • 10
    • 0036317484 scopus 로고    scopus 로고
    • The central roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the metabolic syndrome: An analysis by structural equation modeling
    • 7
    • JC Chan JC Cheung CD Stehouwer JJ Emeis PC Tong GT Ko JS Yudkin 2002 The central roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the metabolic syndrome: an analysis by structural equation modeling Int J Obes Relat Metab Disord 26 7 994 1008
    • (2002) Int J Obes Relat Metab Disord , vol.26 , pp. 994-1008
    • Chan, J.C.1    Cheung, J.C.2    Stehouwer, C.D.3    Emeis, J.J.4    Tong, P.C.5    Ko, G.T.6    Yudkin, J.S.7
  • 11
    • 0037652287 scopus 로고    scopus 로고
    • Inflammation, the metabolic syndrome and cardiovascular risk
    • RP Tracy 2003 Inflammation, the metabolic syndrome and cardiovascular risk Int J Clin Pract Suppl 134 10 17
    • (2003) Int J Clin Pract Suppl , vol.134 , pp. 10-17
    • Tracy, R.P.1
  • 12
    • 35448982744 scopus 로고    scopus 로고
    • Atherosclerosis pathophysiology and the role of novel risk factors: A clinicobiochemical perspective
    • 5
    • V Mallika B Goswami M Rajappa 2007 Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective Angiology 58 5 513 522
    • (2007) Angiology , vol.58 , pp. 513-522
    • Mallika, V.1    Goswami, B.2    Rajappa, M.3
  • 14
    • 4544373257 scopus 로고    scopus 로고
    • Prevalence of non-traditional cardiovascular risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: Analysis of the Third National Health and Nutrition Examination Survey (NHANES III)
    • 9
    • P Muntner J He J Chen V Fonseca PK Whelton 2004 Prevalence of non-traditional cardiovascular risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III) Ann Epidemiol 14 9 686 695
    • (2004) Ann Epidemiol , vol.14 , pp. 686-695
    • Muntner, P.1    He, J.2    Chen, J.3    Fonseca, V.4    Whelton, P.K.5
  • 15
    • 0141723637 scopus 로고    scopus 로고
    • Role of endothelial dysfunction in insulin resistance
    • WA Hsueh MJ Quinones 2003 Role of endothelial dysfunction in insulin resistance Am J Cardiol 92 10J 17J
    • (2003) Am J Cardiol , vol.92
    • Hsueh, W.A.1    Quinones, M.J.2
  • 16
    • 36049004221 scopus 로고    scopus 로고
    • Inflamed adipose tissue: A culprit underlying the metabolic syndrome and atherosclerosis
    • 11
    • B Gustafson A Hammarstedt CX Andersson U Smith 2007 Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis Arterioscler Thromb Vasc Biol 27 11 2276 2283
    • (2007) Arterioscler Thromb Vasc Biol , vol.27 , pp. 2276-2283
    • Gustafson, B.1    Hammarstedt, A.2    Andersson, C.X.3    Smith, U.4
  • 17
    • 0037078969 scopus 로고    scopus 로고
    • Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events
    • PM Ridker N Rifai L Rose JE Buring NR Cook 2002 Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 347 1557 1565
    • (2002) N Engl J Med , vol.347 , pp. 1557-1565
    • Ridker, P.M.1    Rifai, N.2    Rose, L.3    Buring, J.E.4    Cook, N.R.5
  • 18
    • 1842587885 scopus 로고    scopus 로고
    • C-reactive protein and other markers of inflammation in the prediction of coronary artery disease
    • J Danesh JG Wheeler GM Hirschfield 2004 C-reactive protein and other markers of inflammation in the prediction of coronary artery disease N Engl J Med 350 1387 1397
    • (2004) N Engl J Med , vol.350 , pp. 1387-1397
    • Danesh, J.1    Wheeler, J.G.2    Hirschfield, G.M.3
  • 20
    • 35748942525 scopus 로고    scopus 로고
    • Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: Common links
    • 6
    • C Vlachopoulos K Rokkas N Ioakeimidis C Stefanadis 2007 Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: common links Eur Urol 52 6 1590 1600
    • (2007) Eur Urol , vol.52 , pp. 1590-1600
    • Vlachopoulos, C.1    Rokkas, K.2    Ioakeimidis, N.3    Stefanadis, C.4
  • 21
    • 34548443699 scopus 로고    scopus 로고
    • Albuminuria and chronic kidney disease in association with the metabolic syndrome
    • 2
    • T Ninomiya Y Kiyohara 2007 Albuminuria and chronic kidney disease in association with the metabolic syndrome J Cardiometab Syndr 2 2 104 107
    • (2007) J Cardiometab Syndr , vol.2 , pp. 104-107
    • Ninomiya, T.1    Kiyohara, Y.2
  • 23
    • 0037078968 scopus 로고    scopus 로고
    • C-reactive protein-to screen or not to screen?
    • L Mosca 2002 C-reactive protein-to screen or not to screen? N Engl J Med 347 1615 1617
    • (2002) N Engl J Med , vol.347 , pp. 1615-1617
    • Mosca, L.1
  • 24
    • 1842483357 scopus 로고    scopus 로고
    • C-reactive protein reassessed
    • AR Tall 2004 C-reactive protein reassessed N Engl J Med 350 1450 1452
    • (2004) N Engl J Med , vol.350 , pp. 1450-1452
    • Tall, A.R.1
  • 25
    • 2942670689 scopus 로고    scopus 로고
    • Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?
    • PM Ridker PW Wilson SM Grundy 2004 Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 109 2818 2825
    • (2004) Circulation , vol.109 , pp. 2818-2825
    • Ridker, P.M.1    Wilson, P.W.2    Grundy, S.M.3
  • 26
    • 0037469232 scopus 로고    scopus 로고
    • Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association
    • TA Pearson GA Mensah RW Alexander 2003 Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 499 511
    • (2003) Circulation , vol.107 , pp. 499-511
    • Pearson, T.A.1    Mensah, G.A.2    Alexander, R.W.3
  • 27
    • 0032943709 scopus 로고    scopus 로고
    • C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue?
    • JS Yudkin CD Stehouwer JJ Emeis SW Coppack 1999 C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19 972 978
    • (1999) Arterioscler Thromb Vasc Biol , vol.19 , pp. 972-978
    • Yudkin, J.S.1    Stehouwer, C.D.2    Emeis, J.J.3    Coppack, S.W.4
  • 28
    • 0037469255 scopus 로고    scopus 로고
    • C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14, 719 initially healthy American women
    • PM Ridker JE Buring NR Cook N Rifai 2003 C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14, 719 initially healthy American women Circulation 107 391 397
    • (2003) Circulation , vol.107 , pp. 391-397
    • Ridker, P.M.1    Buring, J.E.2    Cook, N.R.3    Rifai, N.4
  • 29
    • 3242662149 scopus 로고    scopus 로고
    • C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study
    • MK Rutter JB Meigs LM Sullivan RB D'Agostino Sr PW Wilson 2004 C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study Circulation 110 380 385
    • (2004) Circulation , vol.110 , pp. 380-385
    • Rutter, M.K.1    Meigs, J.B.2    Sullivan, L.M.3    D'Agostino Sr, R.B.4    Wilson, P.W.5
  • 30
    • 0037078969 scopus 로고    scopus 로고
    • Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events
    • PM Ridker N Rifai L Rose JE Buring NR Cook 2002 Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 347 1557 1565
    • (2002) N Engl J Med , vol.347 , pp. 1557-1565
    • Ridker, P.M.1    Rifai, N.2    Rose, L.3    Buring, J.E.4    Cook, N.R.5
  • 31
  • 33
    • 0041695231 scopus 로고    scopus 로고
    • Emerging risk factors for atherosclerotic vascular disease: A critical review of the evidence
    • 7
    • DG Hackam SS Anand 2003 Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence JAMA 290 7 932 940
    • (2003) JAMA , vol.290 , pp. 932-940
    • Hackam, D.G.1    Anand, S.S.2
  • 34
    • 0036645047 scopus 로고    scopus 로고
    • Need to test the inflammation hypothesis
    • DL Bhatt EJ Topol 2002 Need to test the inflammation hypothesis Circulation 106 136 140
    • (2002) Circulation , vol.106 , pp. 136-140
    • Bhatt, D.L.1    Topol, E.J.2
  • 35
    • 0020060090 scopus 로고
    • Identification of multiple subclasses of plasma low density lipoproteins in normal humans
    • RM Krauss DJ Burke 1982 Identification of multiple subclasses of plasma low density lipoproteins in normal humans J Lipid Res 23 97 104
    • (1982) J Lipid Res , vol.23 , pp. 97-104
    • Krauss, R.M.1    Burke, D.J.2
  • 36
    • 31144439939 scopus 로고    scopus 로고
    • Low-density-lipoproteins size and cardiovascular risk assessment
    • M Rizzo K Berneis 2006 Low-density-lipoproteins size and cardiovascular risk assessment QJM-Int J Med 99 1 14
    • (2006) QJM-Int J Med , vol.99 , pp. 1-14
    • Rizzo, M.1    Berneis, K.2
  • 37
    • 0025328877 scopus 로고
    • Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation
    • BA Griffin MJ Caslake B Yip GW Tait CJ Packard J Shepherd 1990 Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation Atherosclerosis 83 59 67
    • (1990) Atherosclerosis , vol.83 , pp. 59-67
    • Griffin, B.A.1    Caslake, M.J.2    Yip, B.3    Tait, G.W.4    Packard, C.J.5    Shepherd, J.6
  • 38
    • 35348812759 scopus 로고    scopus 로고
    • Who needs to care about small, dense low density lipoproteins?
    • M Rizzo K Berneis 2007 Who needs to care about small, dense low density lipoproteins? Int J Clin Pract 61 1949 1956
    • (2007) Int J Clin Pract , vol.61 , pp. 1949-1956
    • Rizzo, M.1    Berneis, K.2
  • 39
    • 0037126526 scopus 로고    scopus 로고
    • Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
    • National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    • National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143-3421
    • (2002) Circulation , vol.106 , pp. 3143-3421
  • 40
    • 0025118667 scopus 로고
    • Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
    • MA Austin MC King KM Vranizan RM Krauss 1990 Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk Circulation 82 495 506
    • (1990) Circulation , vol.82 , pp. 495-506
    • Austin, M.A.1    King, M.C.2    Vranizan, K.M.3    Krauss, R.M.4
  • 41
    • 31144471875 scopus 로고    scopus 로고
    • Lipid triad or atherogenic lipoprotein phenotype: A role in cardiovascular prevention?
    • M Rizzo K Berneis 2005 Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention? J Atheroscl Thromb 12 237 239
    • (2005) J Atheroscl Thromb , vol.12 , pp. 237-239
    • Rizzo, M.1    Berneis, K.2
  • 42
    • 0032102158 scopus 로고    scopus 로고
    • The atherogenic lipoprotein phenotype and vascular endothelial dysfunction
    • N Sattar JR Petrie AJ Jaap 1998 The atherogenic lipoprotein phenotype and vascular endothelial dysfunction Atherosclerosis 138 229 235
    • (1998) Atherosclerosis , vol.138 , pp. 229-235
    • Sattar, N.1    Petrie, J.R.2    Jaap, A.J.3
  • 43
    • 0029828488 scopus 로고    scopus 로고
    • Beyond LDL cholesterol reduction
    • HR Superko 1996 Beyond LDL cholesterol reduction Circulation 94 2351 2354
    • (1996) Circulation , vol.94 , pp. 2351-2354
    • Superko, H.R.1
  • 44
    • 33749004261 scopus 로고    scopus 로고
    • Options for therapeutic intervention: How effective are the different agents?
    • P Barter 2006 Options for therapeutic intervention: how effective are the different agents? Eur Heart J Suppl 8 F47 F53
    • (2006) Eur Heart J Suppl , vol.8
    • Barter, P.1
  • 45
    • 0039228154 scopus 로고    scopus 로고
    • Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system
    • T Bjornheden A Babyi G Bondjers O Wiklund 1996 Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system Atherosclerosis 123 43 56
    • (1996) Atherosclerosis , vol.123 , pp. 43-56
    • Bjornheden, T.1    Babyi, A.2    Bondjers, G.3    Wiklund, O.4
  • 46
    • 0031809817 scopus 로고    scopus 로고
    • Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: A potential mechanism for increased atherogenicity
    • NF Galeano M Al-Haideri F Keyserman SC Rumsey RJ Deckelbaum 1998 Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity J Lipid Res 39 1263 1273
    • (1998) J Lipid Res , vol.39 , pp. 1263-1273
    • Galeano, N.F.1    Al-Haideri, M.2    Keyserman, F.3    Rumsey, S.C.4    Deckelbaum, R.J.5
  • 48
    • 0035254845 scopus 로고    scopus 로고
    • Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins
    • DL Tribble M Rizzo A Chait DM Lewis PJ Blanche RM Krauss 2001 Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins Am J Med 110 103 110
    • (2001) Am J Med , vol.110 , pp. 103-110
    • Tribble, D.L.1    Rizzo, M.2    Chait, A.3    Lewis, D.M.4    Blanche, P.J.5    Krauss, R.M.6
  • 49
    • 0026682450 scopus 로고
    • Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size
    • DL Tribble LG Holl PD Wood RM Krauss 1992 Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size Atherosclerosis 93 189 199
    • (1992) Atherosclerosis , vol.93 , pp. 189-199
    • Tribble, D.L.1    Holl, L.G.2    Wood, P.D.3    Krauss, R.M.4
  • 51
    • 0242288750 scopus 로고    scopus 로고
    • Low-density lipoprotein size and cardiovascular disease: A reappraisal
    • FM Sacks H Campos 2003 Low-density lipoprotein size and cardiovascular disease: a reappraisal J Clin Endocr Metab 88 4525 4532
    • (2003) J Clin Endocr Metab , vol.88 , pp. 4525-4532
    • Sacks, F.M.1    Campos, H.2
  • 52
    • 40749103679 scopus 로고    scopus 로고
    • Detection of small, dense LDL-cholesterol: Is it necessary to determine particle size?
    • T Wierzbicki 2008 Detection of small, dense LDL-cholesterol: is it necessary to determine particle size? Future Lipidol 3 23 25
    • (2008) Future Lipidol , vol.3 , pp. 23-25
    • Wierzbicki, T.1
  • 53
    • 27444443876 scopus 로고    scopus 로고
    • American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
    • SM Grundy JI Cleeman SR Daniels KA Donato RH Eckel BA Franklin DJ Gordon RM Krauss PJ Savage SC Smith Jr JA Spertus F Costa 2005 American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation 112 2735 2752
    • (2005) Circulation , vol.112 , pp. 2735-2752
    • Grundy, S.M.1    Cleeman, J.I.2    Daniels, S.R.3    Donato, K.A.4    Eckel, R.H.5    Franklin, B.A.6    Gordon, D.J.7    Krauss, R.M.8    Savage, P.J.9    Smith Jr, S.C.10    Spertus, J.A.11    Costa, F.12
  • 54
    • 0028886424 scopus 로고
    • A preponderance of small dense LDL is associated with specific insulin, proinsulin and the components of the insulin resistance syndrome in non-diabetic subjects
    • SM Haffner L Mykkanen D Robbins R Valdez H Miettinen BV Howard MP Stern R Bowsher 1995 A preponderance of small dense LDL is associated with specific insulin, proinsulin and the components of the insulin resistance syndrome in non-diabetic subjects Diabetologia 38 1328 1336
    • (1995) Diabetologia , vol.38 , pp. 1328-1336
    • Haffner, S.M.1    Mykkanen, L.2    Robbins, D.3    Valdez, R.4    Miettinen, H.5    Howard, B.V.6    Stern, M.P.7    Bowsher, R.8
  • 55
    • 0033818023 scopus 로고    scopus 로고
    • The metabolic syndrome, LDL particle size, and atherosclerosis: The Atherosclerosis and Insulin Resistance (AIR) study
    • J Hulthe L Bokemark J Wikstrand B Fagerberg 2000 The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study Arterioscler Thromb Vasc Biol 20 2140 2147
    • (2000) Arterioscler Thromb Vasc Biol , vol.20 , pp. 2140-2147
    • Hulthe, J.1    Bokemark, L.2    Wikstrand, J.3    Fagerberg, B.4
  • 56
    • 59449105735 scopus 로고    scopus 로고
    • World Health Organization. World Health Org Geneva
    • World Health Organization (1999) Definition, diagnosis, and classification of diabetes mellitus and its complications: report of a WHO consultation. World Health Org, Geneva
    • (1999)
  • 57
    • 17844367328 scopus 로고    scopus 로고
    • Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome
    • MC Garin B Kalix A Morabia RW James 2005 Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome J Clin Endocrinol Metab 90 2264 2269
    • (2005) J Clin Endocrinol Metab , vol.90 , pp. 2264-2269
    • Garin, M.C.1    Kalix, B.2    Morabia, A.3    James, R.W.4
  • 58
    • 33644911825 scopus 로고    scopus 로고
    • Prevalence of cardiovascular risk factors in coronary heart disease patients with different low-density lipoprotein phenotypes
    • R Slapikas D Luksiene B Slapikiene MR Babarskiene R Grybauskiene L Linoniene 2005 Prevalence of cardiovascular risk factors in coronary heart disease patients with different low-density lipoprotein phenotypes Medicina (Kaunas) 41 925 931
    • (2005) Medicina (Kaunas) , vol.41 , pp. 925-931
    • Slapikas, R.1    Luksiene, D.2    Slapikiene, B.3    Babarskiene, M.R.4    Grybauskiene, R.5    Linoniene, L.6
  • 59
    • 33745140143 scopus 로고    scopus 로고
    • Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria
    • I Gazi V Tsimihodimos T Filippatos E Bairaktari AD Tselepis M Elisaf 2006 Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria Metabolism 55 885 891
    • (2006) Metabolism , vol.55 , pp. 885-891
    • Gazi, I.1    Tsimihodimos, V.2    Filippatos, T.3    Bairaktari, E.4    Tselepis, A.D.5    Elisaf, M.6
  • 60
    • 35348843962 scopus 로고    scopus 로고
    • Factors influencing the formation of small dense low-density lipoprotein particles in dependence on the presence of the metabolic syndrome and on the degree of glucose intolerance
    • U Julius M Dittrich J Pietzsch 2007 Factors influencing the formation of small dense low-density lipoprotein particles in dependence on the presence of the metabolic syndrome and on the degree of glucose intolerance Int J Clin Pract 61 1798 1804
    • (2007) Int J Clin Pract , vol.61 , pp. 1798-1804
    • Julius, U.1    Dittrich, M.2    Pietzsch, J.3
  • 62
    • 27744595682 scopus 로고    scopus 로고
    • Beyond low-density lipoprotein: Addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome
    • RW Nesto 2005 Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome Am J Cardiovasc Drugs 5 379 387
    • (2005) Am J Cardiovasc Drugs , vol.5 , pp. 379-387
    • Nesto, R.W.1
  • 63
    • 10044240704 scopus 로고    scopus 로고
    • Comparative effects of lipid-lowering therapies
    • Davidson MH, Toth PP (2004) Comparative effects of lipid-lowering therapies. Prog Cardiovasc Dis 47: 73-104
    • (2004) Prog Cardiovasc Dis , vol.47 , pp. 73-104
    • Davidson, M.H.1    Toth, P.P.2
  • 64
    • 34249067115 scopus 로고    scopus 로고
    • The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates
    • M Rizzo K Berneis 2007 The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates Curr Med Res Opin 23 1103 1111
    • (2007) Curr Med Res Opin , vol.23 , pp. 1103-1111
    • Rizzo, M.1    Berneis, K.2
  • 65
    • 40749106944 scopus 로고    scopus 로고
    • Do statins reduce events in patients with metabolic syndrome?
    • 1
    • SP Towne E Thara 2008 Do statins reduce events in patients with metabolic syndrome? Curr Atheroscler Rep 10 1 39 44
    • (2008) Curr Atheroscler Rep , vol.10 , pp. 39-44
    • Towne, S.P.1    Thara, E.2
  • 66
    • 33746465844 scopus 로고    scopus 로고
    • The clinical relevance of low-density-lipoproteins size modulation by statins
    • M Rizzo K Berneis 2006 The clinical relevance of low-density-lipoproteins size modulation by statins Cardiovasc Drug Ther 20 205 217
    • (2006) Cardiovasc Drug Ther , vol.20 , pp. 205-217
    • Rizzo, M.1    Berneis, K.2
  • 67
    • 0037099259 scopus 로고    scopus 로고
    • Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial
    • 2
    • RS Rosenson JD Otvos DS Freedman 2002 Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial Am J Cardiol 90 2 89 94
    • (2002) Am J Cardiol , vol.90 , pp. 89-94
    • Rosenson, R.S.1    Otvos, J.D.2    Freedman, D.S.3
  • 68
    • 0029823744 scopus 로고    scopus 로고
    • Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project
    • BD Miller EL Alderman WL Haskell JM Fair RM Krauss 1996 Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project Circulation 94 2146 2153
    • (1996) Circulation , vol.94 , pp. 2146-2153
    • Miller, B.D.1    Alderman, E.L.2    Haskell, W.L.3    Fair, J.M.4    Krauss, R.M.5
  • 69
    • 0033586641 scopus 로고    scopus 로고
    • Evidence for a new pathophysiological mechanism for coronary artery disease regression: Hepatic lipase-mediated changes in LDL density
    • A Zambon JE Hokanson BG Brown JD Brunzell 1999 Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density Circulation 99 1959 1964
    • (1999) Circulation , vol.99 , pp. 1959-1964
    • Zambon, A.1    Hokanson, J.E.2    Brown, B.G.3    Brunzell, J.D.4
  • 70
    • 0033669366 scopus 로고    scopus 로고
    • Therapeutic modulation of low-density lipoprotein size
    • AD Marais 2000 Therapeutic modulation of low-density lipoprotein size Curr Opin Lipidol 11 597 602
    • (2000) Curr Opin Lipidol , vol.11 , pp. 597-602
    • Marais, A.D.1
  • 71
    • 0026597808 scopus 로고
    • Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study
    • V Manninen L Tenkanen P Koskinen 1992 Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study Circulation 85 37 45
    • (1992) Circulation , vol.85 , pp. 37-45
    • Manninen, V.1    Tenkanen, L.2    Koskinen, P.3
  • 72
    • 0029127208 scopus 로고
    • Some coronary risk factors related to the insulin resistance syndrome and the treatment with gemfibrozil. Experience from the Helsinki Heart Study
    • L Tenkanen M Manttari V Manninen 1995 Some coronary risk factors related to the insulin resistance syndrome and the treatment with gemfibrozil. Experience from the Helsinki Heart Study Circulation 92 1779 1785
    • (1995) Circulation , vol.92 , pp. 1779-1785
    • Tenkanen, L.1    Manttari, M.2    Manninen, V.3
  • 73
    • 0033527030 scopus 로고    scopus 로고
    • Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol: Veterans affairs high-density lipoprotein cholesterol intervention trials study group
    • HB Rubins SJ Robins D Collins 1999 Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol: Veterans affairs high-density lipoprotein cholesterol intervention trials study group N Engl J Med 341 410 418
    • (1999) N Engl J Med , vol.341 , pp. 410-418
    • Rubins, H.B.1    Robins, S.J.2    Collins, D.3
  • 74
    • 42049088250 scopus 로고    scopus 로고
    • Novel molecules targeting dyslipidemia and atherosclerosis
    • 8
    • A Tavridou VG Manolopoulos 2008 Novel molecules targeting dyslipidemia and atherosclerosis Curr Med Chem 15 8 792 802
    • (2008) Curr Med Chem , vol.15 , pp. 792-802
    • Tavridou, A.1    Manolopoulos, V.G.2
  • 75
    • 24644499056 scopus 로고    scopus 로고
    • Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome
    • 2
    • AJ Drexler RW Nesto MJ Abrahamson 2005 Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome Metab Syndr Relat Disord 3 2 147 173
    • (2005) Metab Syndr Relat Disord , vol.3 , pp. 147-173
    • Drexler, A.J.1    Nesto, R.W.2    Abrahamson, M.J.3
  • 76
    • 2542492541 scopus 로고    scopus 로고
    • Lipids and lipoproteins in patients with type 2 diabetes
    • RM Krauss 2004 Lipids and lipoproteins in patients with type 2 diabetes Diabetes Care 27 1496 1504
    • (2004) Diabetes Care , vol.27 , pp. 1496-1504
    • Krauss, R.M.1
  • 77
    • 0033754530 scopus 로고    scopus 로고
    • Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study
    • S Aronoff S Rosenblatt S Braithwaite 2000 Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study Diabetes Care 23 1605 1611
    • (2000) Diabetes Care , vol.23 , pp. 1605-1611
    • Aronoff, S.1    Rosenblatt, S.2    Braithwaite, S.3
  • 78
    • 0036244970 scopus 로고    scopus 로고
    • Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes
    • FJ Gomez-Perez G Fanghanel-Salmon JA Barbosa 2002 Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes Diabetes Metab Res Rev 18 127 134
    • (2002) Diabetes Metab Res Rev , vol.18 , pp. 127-134
    • Gomez-Perez, F.J.1    Fanghanel-Salmon, G.2    Barbosa, J.A.3
  • 79
    • 21544466158 scopus 로고    scopus 로고
    • A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
    • RB Goldberg DM Kendall MA Deeg 2005 A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia Diabetes Care 28 1547 1554
    • (2005) Diabetes Care , vol.28 , pp. 1547-1554
    • Goldberg, R.B.1    Kendall, D.M.2    Deeg, M.A.3
  • 80
    • 7044253431 scopus 로고    scopus 로고
    • A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors
    • E Chiquette G Ramirez R Defronzo 2004 A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors Arch Intern Med 164 2097 2104
    • (2004) Arch Intern Med , vol.164 , pp. 2097-2104
    • Chiquette, E.1    Ramirez, G.2    Defronzo, R.3
  • 81
    • 35148837113 scopus 로고    scopus 로고
    • On behalf of the GLAI Study Investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia
    • MA Deeg JB Buse RB Goldberg 2007 On behalf of the GLAI Study Investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia Diabetes Care 30 2458 2464
    • (2007) Diabetes Care , vol.30 , pp. 2458-2464
    • Deeg, M.A.1    Buse, J.B.2    Goldberg, R.B.3
  • 82
    • 39049126602 scopus 로고    scopus 로고
    • Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with type-2 diabetes
    • K Berneis M Rizzo C Stettler B Chappuis M Braun P Diem ER Christ 2008 Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with type-2 diabetes Expert Opin Pharmacother 9 343 349
    • (2008) Expert Opin Pharmacother , vol.9 , pp. 343-349
    • Berneis, K.1    Rizzo, M.2    Stettler, C.3    Chappuis, B.4    Braun, M.5    Diem, P.6    Christ, E.R.7
  • 83
    • 17044410540 scopus 로고    scopus 로고
    • Treatment of the metabolic syndrome: The impact of lifestyle modification
    • 2
    • AM Pritchett JP Foreyt DL Mann 2005 Treatment of the metabolic syndrome: the impact of lifestyle modification Curr Atheroscler Rep 7 2 95 102
    • (2005) Curr Atheroscler Rep , vol.7 , pp. 95-102
    • Pritchett, A.M.1    Foreyt, J.P.2    Mann, D.L.3
  • 84
    • 14744284119 scopus 로고    scopus 로고
    • Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects
    • 1
    • JW Chu F Abbasi C Lamendola T McLaughlin GM Reaven PS Tsao 2005 Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects Diab Vasc Dis Res 2 1 37 41
    • (2005) Diab Vasc Dis Res , vol.2 , pp. 37-41
    • Chu, J.W.1    Abbasi, F.2    Lamendola, C.3    McLaughlin, T.4    Reaven, G.M.5    Tsao, P.S.6
  • 85
    • 0037732481 scopus 로고    scopus 로고
    • The adipocyte in insulin reistance: Key molecules and the impact of the thiazolidinediones
    • 3
    • P Arner 2003 The adipocyte in insulin reistance: key molecules and the impact of the thiazolidinediones TRENDS in Endocrinol Metab 14 3 137 145
    • (2003) TRENDS in Endocrinol Metab , vol.14 , pp. 137-145
    • Arner, P.1
  • 87
    • 38449107525 scopus 로고    scopus 로고
    • PPAR agonists and the metabolic syndrome
    • 4
    • B Staels 2007 PPAR agonists and the metabolic syndrome Therapie 62 4 319 326
    • (2007) Therapie , vol.62 , pp. 319-326
    • Staels, B.1
  • 88
    • 35548942603 scopus 로고    scopus 로고
    • Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: The role of PPAR-alpha
    • Suppl 3
    • J Plutzky 2007 Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPAR-alpha Diab Vasc Dis Res 4 Suppl 3 S12 S14
    • (2007) Diab Vasc Dis Res , vol.4
    • Plutzky, J.1
  • 89
    • 3142550830 scopus 로고    scopus 로고
    • Fibrates for treatment of the metabolic syndrome
    • 1
    • KC Maki 2004 Fibrates for treatment of the metabolic syndrome Curr Atheroscler Rep J 6 1 45 51
    • (2004) Curr Atheroscler Rep J , vol.6 , pp. 45-51
    • Maki, K.C.1
  • 90
    • 0027987849 scopus 로고
    • Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S)
    • Scandinavian Simvastatin Survival Study Group
    • Scandinavian Simvastatin Survival Study Group 1994 Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S) Lancet 344 1383 1389
    • (1994) Lancet , vol.344 , pp. 1383-1389
  • 91
    • 23944438863 scopus 로고    scopus 로고
    • Relation of C-reactive protein and one-year survival after acute myocardial infarction with versus without statin therapy
    • Osaka Acute Coronary Insufficiency Study (OACIS) Group. 5
    • K Kinjo H Sato Y Sakata D Nakatani H Mizuno M Shimizu M Nishino H Ito J Tanouchi S Nanto M Hori Osaka Acute Coronary Insufficiency Study (OACIS) Group 2005 Relation of C-reactive protein and one-year survival after acute myocardial infarction with versus without statin therapy Am J Cardiol 96 5 617 621
    • (2005) Am J Cardiol , vol.96 , pp. 617-621
    • Kinjo, K.1    Sato, H.2    Sakata, Y.3    Nakatani, D.4    Mizuno, H.5    Shimizu, M.6    Nishino, M.7    Ito, H.8    Tanouchi, J.9    Nanto, S.10    Hori, M.11
  • 92
    • 23244446639 scopus 로고    scopus 로고
    • The effects of statins on endothelium, inflammation, and cardioprotection
    • 4
    • JW Elrod DJ Lefer 2005 The effects of statins on endothelium, inflammation, and cardioprotection Drugs News Perspect 18 4 229 236
    • (2005) Drugs News Perspect , vol.18 , pp. 229-236
    • Elrod, J.W.1    Lefer, D.J.2
  • 93
    • 0035901619 scopus 로고    scopus 로고
    • Effects of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels
    • I Jialal D Stein D Balis SM Grundy B Adams-Huet S Devaraj 2001 Effects of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels Circulation 103 1933 1935
    • (2001) Circulation , vol.103 , pp. 1933-1935
    • Jialal, I.1    Stein, D.2    Balis, D.3    Grundy, S.M.4    Adams-Huet, B.5    Devaraj, S.6
  • 94
    • 34548088328 scopus 로고    scopus 로고
    • Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women
    • 4
    • M Bougoulia A Triantos G Koliakos 2006 Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women Hormones (Athens) 5 4 259 269
    • (2006) Hormones (Athens) , vol.5 , pp. 259-269
    • Bougoulia, M.1    Triantos, A.2    Koliakos, G.3
  • 95
    • 1842479689 scopus 로고    scopus 로고
    • Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines
    • 4
    • G Valsamakis PG McTernan R Chetty 2004 Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines Metabolism 53 4 430 434
    • (2004) Metabolism , vol.53 , pp. 430-434
    • Valsamakis, G.1    McTernan, P.G.2    Chetty, R.3
  • 96
    • 41149130137 scopus 로고    scopus 로고
    • Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: Pooled 1-year data from the Rimonabant in Obesity (RIO) program
    • Suppl 2
    • L Van Gaal X Pi-Sunyer JP Després C McCarthy A Scheen 2008 Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program Diabetes Care 31 Suppl 2 S229 S240
    • (2008) Diabetes Care , vol.31
    • Van Gaal, L.1    Pi-Sunyer, X.2    Després, J.P.3    McCarthy, C.4    Scheen, A.5
  • 97
    • 40749085693 scopus 로고    scopus 로고
    • Endocannabinoid system overactivity and the metabolic syndrome: Prospects for treatment
    • 1
    • JM Perkins SN Davis 2008 Endocannabinoid system overactivity and the metabolic syndrome: prospects for treatment Curr Diab Rep 8 1 12 19
    • (2008) Curr Diab Rep , vol.8 , pp. 12-19
    • Perkins, J.M.1    Davis, S.N.2
  • 98
    • 24344460376 scopus 로고    scopus 로고
    • Protective effects of angiotensin II interruption: Evidence for antiinflammatory actions
    • 9
    • NJ Dagenais F Jamali 2005 Protective effects of angiotensin II interruption: evidence for antiinflammatory actions Pharmacotherapy 25 9 1213 1229
    • (2005) Pharmacotherapy , vol.25 , pp. 1213-1229
    • Dagenais, N.J.1    Jamali, F.2
  • 99
    • 23844436724 scopus 로고    scopus 로고
    • Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers
    • 5
    • C Sierra A de la Sierra 2005 Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers Curr Opin Nephrol Hypertens 14 5 435 441
    • (2005) Curr Opin Nephrol Hypertens , vol.14 , pp. 435-441
    • Sierra, C.1    De La Sierra, A.2
  • 100
    • 4344582057 scopus 로고    scopus 로고
    • Position statement on the insulin resistance syndrome
    • American College of Endocrinology (ACE). No. 3
    • American College of Endocrinology (ACE) 2003 Position statement on the insulin resistance syndrome Endocr Pract 9 No. 3 236 252
    • (2003) Endocr Pract , vol.9 , pp. 236-252
  • 101
    • 10644219570 scopus 로고    scopus 로고
    • Lipaemia, inflammation and atherosclerosis: Novel opportunities in the understanding and treatment of atherosclerosis
    • Suppl 2
    • AJ van Oostrom J van Wijk MC Cabezas 2004 Lipaemia, inflammation and atherosclerosis: novel opportunities in the understanding and treatment of atherosclerosis Drugs 64 Suppl 2 19 41
    • (2004) Drugs , vol.64 , pp. 19-41
    • Van Oostrom, A.J.1    Van Wijk, J.2    Cabezas, M.C.3
  • 102
    • 0038607495 scopus 로고    scopus 로고
    • Insulin resistance as a proinflammatory state: Mechanisms, mediators, and therapeutic interventions
    • 6
    • R Garg D Tripathy P Dandona 2003 Insulin resistance as a proinflammatory state: mechanisms, mediators, and therapeutic interventions Curr Drug Targets 4 6 487 492
    • (2003) Curr Drug Targets , vol.4 , pp. 487-492
    • Garg, R.1    Tripathy, D.2    Dandona, P.3
  • 103
    • 85026133510 scopus 로고    scopus 로고
    • Novel risk factors for coronary heart disease: Emerging connections
    • 2
    • S Hughes 2000 Novel risk factors for coronary heart disease: emerging connections J Cardiovasc Nurs 14 2 91 103
    • (2000) J Cardiovasc Nurs , vol.14 , pp. 91-103
    • Hughes, S.1
  • 104
    • 34248193944 scopus 로고    scopus 로고
    • Circulating small dense LDL, endothelial injuring factors and fibronectin in healthy postmenopausal women
    • 2
    • ML Muzzio G Berg V Zago 2007 Circulating small dense LDL, endothelial injuring factors and fibronectin in healthy postmenopausal women Clin Chim Acta 381 2 157 163
    • (2007) Clin Chim Acta , vol.381 , pp. 157-163
    • Muzzio, M.L.1    Berg, G.2    Zago, V.3
  • 105
    • 42049098909 scopus 로고    scopus 로고
    • The roles of oxidized low-density lipoprotein and interleukin-6 levels in acute atherothrombotic and lacunar ischemic stroke
    • 2
    • B Guldiken S Guldiken B Turgut 2008 The roles of oxidized low-density lipoprotein and interleukin-6 levels in acute atherothrombotic and lacunar ischemic stroke Angiology 59 2 224 229
    • (2008) Angiology , vol.59 , pp. 224-229
    • Guldiken, B.1    Guldiken, S.2    Turgut, B.3
  • 107
    • 41549090967 scopus 로고    scopus 로고
    • Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein
    • 3
    • P Dandona 2008 Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein Mayo Clin Proc 83 3 333 342
    • (2008) Mayo Clin Proc , vol.83 , pp. 333-342
    • Dandona, P.1
  • 108
    • 43049118952 scopus 로고    scopus 로고
    • Cross-talk between statins and PPAR-alpha in cardiovascular diseases: Clinical evidence and basic mechanisms
    • 3
    • R Paumelle B Staels 2008 Cross-talk between statins and PPAR-alpha in cardiovascular diseases: clinical evidence and basic mechanisms Trends Cardiovasc Med 18 3 73 78
    • (2008) Trends Cardiovasc Med , vol.18 , pp. 73-78
    • Paumelle, R.1    Staels, B.2
  • 109
    • 5644241067 scopus 로고    scopus 로고
    • The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia
    • B Okopien R Krysiak J Kowalski 2004 The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia Atherosclerosis 176 327 335
    • (2004) Atherosclerosis , vol.176 , pp. 327-335
    • Okopien, B.1    Krysiak, R.2    Kowalski, J.3
  • 110
    • 33646817773 scopus 로고    scopus 로고
    • Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway
    • R Paumelle C Blanquart O Briand 2006 Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway Circ Res 98 361 369
    • (2006) Circ Res , vol.98 , pp. 361-369
    • Paumelle, R.1    Blanquart, C.2    Briand, O.3
  • 111
    • 34249723258 scopus 로고    scopus 로고
    • Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages
    • M Yano T Matsumura T Senokuchi 2007 Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages Circ Res 100 1442 1451
    • (2007) Circ Res , vol.100 , pp. 1442-1451
    • Yano, M.1    Matsumura, T.2    Senokuchi, T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.